Detalhe da pesquisa
1.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature;
603(7903): 934-941, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35130560
2.
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.
Blood;
137(17): 2321-2325, 2021 04 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33512414
3.
Probing the Dynamics and Structural Topology of the Reconstituted Human KCNQ1 Voltage Sensor Domain (Q1-VSD) in Lipid Bilayers Using Electron Paramagnetic Resonance Spectroscopy.
Biochemistry;
58(7): 965-973, 2019 02 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30620191
4.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Cancer Cell;
42(1): 35-51.e8, 2024 01 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38134936
5.
Unravelling human hematopoietic progenitor cell diversity through association with intrinsic regulatory factors.
bioRxiv;
2023 Aug 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37693547
6.
Integrating transcription-factor abundance with chromatin accessibility in human erythroid lineage commitment.
Cell Rep Methods;
2(3)2022 03 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35463156
7.
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.
Nat Med;
28(9): 1860-1871, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36097223
8.
Chromatin accessibility associates with protein-RNA correlation in human cancer.
Nat Commun;
12(1): 5732, 2021 09 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34593797
9.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Nat Med;
27(8): 1419-1431, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34312556
10.
Characterization of the Human KCNQ1 Voltage Sensing Domain (VSD) in Lipodisq Nanoparticles for Electron Paramagnetic Resonance (EPR) Spectroscopic Studies of Membrane Proteins.
J Phys Chem B;
124(12): 2331-2342, 2020 03 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32130007